SCHEDULE: Samsara BioCapital Reduces VTV Therapeutics Stake

Samsara BioCapital, L.P. reported a sale of 75,965 shares of VTV Therapeutics Class A Common Stock at $21.25 per share in a private transaction.

Summary

• Samsara BioCapital, L.P. sold 75,965 shares of VTV Therapeutics Class A Common Stock on December 8, 2025.
• The shares were sold at a price of $21.25 per share in a private transaction.
• These shares were held by Samsara LP for the exclusive benefit of limited partners who had redeemed their interests.
• Neither Samsara BioCapital GP, LLC nor Dr. Srinivas Akkaraju had any economic interest in the sold shares.
• As of the event date, Srinivas Akkaraju beneficially owns 403,942 shares, representing 9.9% of the Class A common stock.
• Samsara BioCapital, L.P. beneficially owns 246,484 shares, representing 6.2% of the Class A common stock.
• Samsara Opportunity Fund, L.P. beneficially owns 152,893 shares, representing 3.8% of the Class A common stock.
• Beneficial ownership percentages are based on 3,938,018 shares outstanding as of November 6, 2025, plus exercisable warrants and options.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant institutional investor reducing its stake, even if the reason is for limited partner redemptions. This could be interpreted by the market as a decrease in conviction, despite the explanation provided.

Positives

• The sale was conducted to facilitate redemptions by limited partners, indicating a structured exit rather than a discretionary divestment by the fund's management.

Negatives

• A significant institutional holder, Samsara BioCapital, L.P., reduced its direct shareholding in VTV Therapeutics.
• The sale of shares by a major investor, even for specific reasons, can be perceived negatively by the market.

Risks

• The reduction in direct shareholding by a major institutional investor could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy.
• The existence of 'Beneficial Ownership Blockers' on warrants limits the ability of Samsara entities to increase their ownership beyond 9.99%, potentially restricting their influence or future investment flexibility.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding VTV Therapeutics' future operations or financial performance, focusing instead on changes in beneficial ownership.

Industry Context

This filing reflects a routine adjustment in an institutional investor's portfolio, specifically related to limited partner redemptions. Such sales are common in the biotechnology investment landscape, where funds manage liquidity and investor exits. The continued significant, albeit reduced, stake held by Samsara BioCapital suggests ongoing interest in VTV Therapeutics, a company likely operating in the biotech or pharmaceutical sector given the investor's name.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership changes by an institutional investor.
• The sale of shares due to limited partner redemptions is a common occurrence in private equity and venture capital funds, aligning with typical fund management practices.
• No specific comparable companies or projects are mentioned in the filing to allow for a direct comparison of results.

Stakeholder Impact

• Shareholders: The reduction in a major investor's stake could lead to negative market sentiment and potentially impact share price.
• Limited Partners of Samsara LP: Those who redeemed their interests received proceeds from the sale.

Next Steps

• No specific future actions or milestones for VTV Therapeutics are mentioned in this filing. The filing details past transactions and current ownership structure.

Key Dates

Recommendation

While a significant institutional investor reduced its stake, the stated reason was for limited partner redemptions, not a fundamental change in the company's prospects. The remaining beneficial ownership by Srinivas Akkaraju and the Samsara entities, including substantial warrant holdings, suggests continued, albeit adjusted, interest. Investors should hold and monitor future developments and the company's operational performance rather than reacting solely to this ownership adjustment.

Keywords

VTV Therapeutics, Samsara BioCapital, Schedule 13D/A, Beneficial Ownership, Stock Sale, Biotechnology, SEC Filing, Institutional Investor, Shareholder Update